Pranax
PranaX is a Houston-based biotechnology company that develops and commercializes stem cell-derived exosome regenerative biologics, licensed from MD Anderson Cancer Center and manufactured in its FDA-registered cGMP facility, sold B2B to aesthetic medicine practitioners and wellness clinics.
- Company typePrivate
- Founded2023
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pranax does
PranaX Corporation is a Houston, Texas-based private biotechnology company developing and commercializing regenerative biologics based on stem cell-derived exosomes (30–150 nm extracellular vesicles). The company's core technology is an exclusive patent license from MD Anderson Cancer Center covering exosome manufacturing, engineering, and non-cancer therapeutic applications, originally developed in a Phase I clinical trial for pancreatic cancer and validated as the first FDA-approved clinical study using mesenchymal stem cell-derived exosomes, with safety data published in Nature Communications. PranaX operates a 7,400 sq ft FDA-registered, cGMP manufacturing facility with a cleanroom suite at the Levit Green life sciences district in the Texas Medical Center, giving it in-house production capacity that is uncommon among early-stage exosome competitors.
The company's product portfolio consists of stem cell-derived exosome products targeted at regenerative dermatology, aesthetic medicine, and healthspan/wellness applications rather than oncology indications. It sells through direct B2B enterprise field-sales relationships with physicians, aesthetic medicine practitioners, and wellness clinics, primarily in the Texas/USA market, with a secondary potential revenue stream from licensing its proprietary manufacturing IP. The company has invested in educational website content and earned-media channels (PRNewswire press releases, newsletter capture) to support physician engagement and stakeholder awareness.
PranaX is led by a C-suite built around exosome manufacturing expertise: CEO Phillip Maderia (formerly of Lonza, where he built Lonza's first 500L-scale GMP exosome process), Founder/COO Dr. Steven J. Greco, PhD (20+ years in stem cell biology), CFO Kenneth Klein, CMO Dr. Richard H. LeConey, MD (aesthetic-medicine pioneer), and Chief Business Officer Thad Johnson. The company has raised approximately $17M in an oversubscribed January 2026 Series A (plus an earlier $15M SEC Form D filing) from family offices, trusts, and individual biotech investors, with proceeds directed to GMP manufacturing scale-up, R&D, and commercialization.
Pranax firmographics
Firmographics- Name
- Pranax
- Legal name
- PranaX Corporation
- Website
- https://pranax.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PranaX is a Houston-based biotechnology company that develops and commercializes stem cell-derived exosome regenerative biologics, licensed from MD Anderson Cancer Center and manufactured in its FDA-registered cGMP facility, sold B2B to aesthetic medicine practitioners and wellness clinics.
- Ownership category
- akta.pro rank
Pranax industry classification
Industry- Product category
- Regenerative Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industry
- Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)
Keywords
Where Pranax is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pranax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Exosome-Based Wellness Products: Sale of stem cell-derived exosome products for regenerative dermatology and wellness applications. Products are commercialized through B2B channels targeting healthcare providers and aesthetic medicine practitioners.
- Licensing Royalties: Technology licensed from MD Anderson Cancer Center provides access to core patent portfolio. Revenue may be generated through licensing of proprietary exosome technology.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Pranax product offering
Product offeringCore offering
PranaX develops and commercializes proprietary stem cell-derived exosome products for regenerative medicine, wellness, and aesthetic applications. The company manufactures exosomes at an FDA-registered, cGMP facility in Houston, Texas, leveraging patented technology exclusively licensed from MD Anderson Cancer Center. Its exosome-based biologics are designed to support immune regulation, tissue regeneration, and neuronal communication for healthcare providers and aesthetic medicine practitioners.
Product overview
PranaX is a biotechnology company offering a unified portfolio of exosome-based regenerative biologics for wellness and healthspan applications. The core offering consists of proprietary stem cell-derived exosome products and technologies, complemented by licensed manufacturing IP from MD Anderson Cancer Center. The company operates its own FDA-registered, cGMP manufacturing facility at the Levit Green life science campus in Houston, Texas. Products target aesthetic medicine, wellness, and healthy aging markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Stem Cell-Derived Exosome Products
Quantifiable outcome
- Safety demonstrated in FDA-approved clinical trial for exosome manufacturing technology
- +1 more outcomes
Companies that use Pranax
Customer profileSegments2 records
Ideal customer profiles1 record
Pranax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pranax partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MD Anderson Cancer CentercorePranaX holds an exclusive technology license from MD Anderson Cancer Center. The license grants access to a core patent portfolio covering exosome manufacturing, engineering and pursuit of non-cancer therapeutic applications. The technology leverages the first FDA-approved clinical study using mesenchymal stem cell-derived exosomes.
Scale indicators3 records
Recent moves3 records
Expansion highlights5 records
Pranax competitors and assessment
Company assessmentDirect peers
- ExoCoBio: Korea-based company commercializing stem cell-derived exosome products for aesthetics, dermatology, and hair restoration. Closely comparable on product format (exosome topicals/injectables) and target customer (aesthetic medicine practitioners).
- Rion Aesthetics: US aesthetics company offering platelet-derived and exosome-based regenerative products (PRP/exosome systems) to med-spas and aesthetic practices. Direct competitor in the physician-dispensed exosome aesthetics channel.
- Capricor Therapeutics: Clinical-stage biotech developing cell-derived extracellular vesicle and exosome-based therapeutics, with a pipeline overlapping MSC-derived biologics for inflammatory and regenerative indications.
- Evox Therapeutics: UK-based biotech engineering exosomes for therapeutic delivery across rare disease and CNS indications. Highly comparable as a fellow developer of engineered exosome therapeutics with pharma partnerships.
- Aegle Therapeutics: US biotech developing stem cell-derived extracellular vesicle therapies for regenerative medicine applications including aesthetics and wound healing. Comparable on MSC-exosome platform and clinical positioning.
Broad incumbents
- Codiak BioSciences (acquired by Lonza): Pioneer in engineered exosome therapeutics; its IP was acquired by Lonza in 2023 after Codiak's closure. Lonza now offers commercial-scale exosome manufacturing services, directly competing with PranaX's manufacturing platform.
- Mesoblast: Commercial-stage cell therapy company using mesenchymal lineage cell platforms for inflammatory and regenerative indications. Comparable on MSC-derived biologic modality and clinical pipeline breadth.
- Pluristem Therapeutics: Cell therapy company developing placenta-derived MSC therapies for regenerative indications. Comparable on MSC-derived regenerative biologics platform and B2B hospital/physician commercialization model.
Emerging players
- Kimera Labs: US-based lab producing MSC-derived exosome and growth factor products sold to physicians and clinics for aesthetic and regenerative applications. Direct overlap in the physician-channel exosome wellness segment.
- Direct Biologics: US-based regenerative medicine company developing MSC-derived extracellular vesicle products (ExoFlo) for inflammatory conditions. Comparable as a peer-stage company selling MSC-derived EV biologics into physician channels.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pranax social profiles
Digital presencePranax compliance and trust
Trust signalCompliance1 record
Pranax financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pranax leadership team
Management profileNumber of profiles
Profiles9 records
Pranax funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pranax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pranax
What does Pranax do?
PranaX develops and commercializes proprietary stem cell-derived exosome products for regenerative medicine, wellness, and aesthetic applications. The company manufactures exosomes at an FDA-registered, cGMP facility in Houston, Texas, leveraging patented technology exclusively licensed from MD Anderson Cancer Center. Its exosome-based biologics are designed to support immune regulation, tissue regeneration, and neuronal communication for healthcare providers and aesthetic medicine practitioners.
Is Pranax a public or private company?
Pranax is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pranax founded?
Pranax was founded in 2023. It employs 11 to 50 people.
Where is Pranax based?
Pranax is headquartered in Houston, United States, in the North America region.
How does Pranax make money?
Two revenue lines are on record. Exosome-Based Wellness Products are the primary driver. The others are licensing Royalties.
Who are Pranax's main competitors?
Direct peers on record are ExoCoBio, Rion Aesthetics, Capricor Therapeutics, Evox Therapeutics and Aegle Therapeutics. Broad incumbents are Codiak BioSciences (acquired by Lonza), Mesoblast and Pluristem Therapeutics. Emerging players are Kimera Labs and Direct Biologics.
Does Pranax have an API?
No public API is recorded for Pranax.
What industry is Pranax in?
Pranax's product category is Regenerative Biologics. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.